In recent years, researchers have explored strategies using CCR2 antagonists to selectively attract suppressive monocytes and macrophages into the tumor, with the goal of altering the tumor microenvironment and enhancing the immune system’s ability to combat cancer (78). The gene discussed is CCR2; the disease is neoplasm.